#Sweden #Stockholm #Sobi #Altuvoct #Doptelet

Sobi Reports Impressive Growth in Q1 2026

Swedish Orphan Biovitrum AB (Sobi®) has announced its financial results for the first quarter of 2026, showcasing substantial revenue growth and a strong performance across various sectors. The report highlights a remarkable increase in total revenue, which rose by 24% at constant exchange rates (CER) to reach SEK 7,184 million, compared to SEK 6,465 million in the same period last year.

Key Highlights of Q1 2026

In the hematology segment, Sobi reported revenue of SEK 5,186 million, reflecting a 24% increase at CER, primarily fueled by the growing sales of Altuvoct and Doptelet. Altuvoct sales reached SEK 1,240 million, while Doptelet generated SEK 1,433 million, marking significant year-over-year growth.

The immunology sector also showed impressive results, with revenues rising by 24% at CER to SEK 1,643 million. This growth was significantly driven by strong sales of Gamifant, which totaled SEK 734 million, and Kineret, with sales of SEK 779 million. Sobi's strategic portfolio further boosted the growth, showing a staggering 55% increase at CER to SEK 4,524 million.

Financial Metrics

The adjusted EBITA margin for Sobi during Q1 increased to 38%, up from 36% in the previous year, excluding items affecting comparability (IAC). The EBITA was reported at SEK 2,612 million with a 36% margin, while the EBIT grew to SEK 1,868 million from SEK 1,358 million. The earnings per share (EPS) before dilution improved to SEK 3.81, up from SEK 2.55, showcasing the company's financial robustness.

Cash flow from operating activities for the quarter was SEK 1,126 million, compared to SEK 2,295 million last year. Additionally, Sobi completed the acquisition of Arthrosi Therapeutics, Inc. during this period, further consolidating its position in the market.

Outlook for 2026

Looking ahead, Sobi maintains its revenue growth forecast for 2026 at a low double-digit percentage at CER, along with expectations for the adjusted EBITA margin to settle in the mid-30s percentage range of revenue. These projections indicate a solid strategy moving forward amidst the evolving biopharmaceutical landscape.

Invitation to Investors

To engage with analysts and media, Sobi invites stakeholders to participate in a conference call, scheduled for April 28, 2026, at 1230 CEST. The call will feature a comprehensive presentation of these results, coupled with a Q&A session. Investors can find the call details on Sobi's official website and attend the presentation live, or catch up later online.

About Sobi

Sobi is a leading global biopharmaceutical company, dedicated to unlocking innovative solutions that transform lives for patients dealing with rare diseases. With a workforce of approximately 2,000 employees operating across various continents, Sobi's performance in 2025 topped SEK 28 billion in revenue, reflecting the company’s extensive reach and commitment to healthcare advancements. The company's stocks are traded on Nasdaq Stockholm under the ticker STOSOBI. More information can be found on sobi.com.

In conclusion, Sobi's Q1 2026 report reflects not only its strong financial growth but also the strategic maneuvers the company is undertaking to position itself favorably in the biopharmaceutical industry, a promising sign for investors and stakeholders alike.